Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019–2020

BACKGROUND: The U.S. Food and Drug Administration (FDA) Biologics Effectiveness and Safety (BEST) Initiative conducts active surveillance of adverse events of special interest (AESI) after COVID-19 vaccination. Historical incidence rates (IRs) of AESI are comparators to evaluate safety. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Moll, Keran, Lufkin, Bradley, Fingar, Kathryn R., Ke Zhou, Cindy, Tworkoski, Ellen, Shi, Chianti, Hobbi, Shayan, Hu, Mao, Sheng, Minya, McCarty, Jillian, Shangguan, Shanlai, Burrell, Timothy, Chillarige, Yoganand, Beers, Jeff, Saunders-Hastings, Patrick, Muthuri, Stella, Edwards, Kathryn, Black, Steven, Kelman, Jeff, Reich, Christian, Amend, Kandace L., Djibo, Djeneba Audrey, Beachler, Daniel, Ogilvie, Rachel P., Secora, Alex, McMahill-Walraven, Cheryl N., Seeger, John D., Lloyd, Patricia, Thompson, Deborah, Dimova, Rositsa, MaCurdy, Thomas, Obidi, Joyce, Anderson, Steve, Forshee, Richard, Wong, Hui-Lee, Shoaibi, Azadeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640387/
https://www.ncbi.nlm.nih.gov/pubmed/36404170
http://dx.doi.org/10.1016/j.vaccine.2022.11.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640387/
https://www.ncbi.nlm.nih.gov/pubmed/36404170
http://dx.doi.org/10.1016/j.vaccine.2022.11.003

Ejemplares similares